The Commodity Futures Trading Commission approved the first regulated Bitcoin perpetual futures contract in the U.S. this week and simultaneously streamlined how crypto product filings are processed. The move pulls a popular offshore derivative onshore, letting American traders trade a contract that never expires through a regulated exchange.
The new filing process
Until now, launching a crypto perpetual futures product meant navigating a slow, case-by-case review. The CFTC's new framework treats these contracts more like standard commodity futures, cutting the paperwork and review timeline. Exchanges won't need to submit individual petitions for each minor tweak to contract specs. That’s a direct response to industry complaints that U.S. rules made it impossible to keep pace with offshore competitors.
Why perpetuals stayed offshore
Perpetual futures are the most traded crypto derivative globally, with daily volume that dwarfs spot markets. But they’ve lived almost entirely on non-U.S. platforms like Binance and Bybit. U.S. rules required exchanges to treat them as swaps, triggering margin and clearing requirements that made them uneconomical. This approval changes that math — at least for the one contract now cleared.
What the approval means
The first contract isn't named to an exchange in the CFTC announcement, but the implication is clear: any U.S. designated contract market can now file under the streamlined rules. The regulator’s move signals it sees perpetuals as a mature product, not an exotic risk. That could push more volume onto regulated venues, though the margin and leverage terms will still be set by the exchange, not the CFTC.
Next on the docket
The contract itself is expected to begin trading within weeks. The CFTC didn’t specify a date, but the streamlined filing process means other exchanges can now rush similar products to market. The real test will be whether traders actually migrate from offshore platforms. For now, the U.S. has its first regulated Bitcoin perpetual future — something that seemed impossible two years ago.
